What is Minerva Neurosciences Forward Dividend Yield %?
As of today (2024-04-29), the Forward Annual Dividend Yield of Minerva Neurosciences is 0.00%.
As of today (2024-04-29), the Trailing Annual Dividend Yield of Minerva Neurosciences is 0.00%.
NERV's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.475 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Minerva Neurosciences's Forward Dividend Yield %
For the Biotechnology subindustry, Minerva Neurosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minerva Neurosciences's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Minerva Neurosciences's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Minerva Neurosciences Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Minerva Neurosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Minerva Neurosciences (Minerva Neurosciences) Business Description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NERV has been successfully added to your